Berenberg Upgrades Sanofi-Aventis (SNY) to Buy; Favorable Risk/Reward

September 8, 2016 6:35 AM EDT
Get Alerts SNY Hot Sheet
Price: $39.77 --0%

Rating Summary:
    6 Buy, 11 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 6 | Down: 11 | New: 1
Trade SNY Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Berenberg upgraded Sanofi-Aventis (NYSE: SNY) from Hold to Buy with a price target of EUR93, saying risk/reward is favraoble.

Analyst Louise Pearson commented, "Sanofi shares have underperformed the healthcare index by 15% over the last 12 months, and have de-rated from 15x to just c13x forward earnings, making it the cheapest stock in our European large-cap universe. This performance is largely due to problems in the diabetes business. While there are still potential bumps in the road ahead, we feel that the shares have been overly discounted. The risk/reward opportunity is now favourable and we see over 30% upside to our price target. We upgrade to Buy."

For an analyst ratings summary and ratings history on Sanofi-Aventis click here. For more ratings news on Sanofi-Aventis click here.

Shares of Sanofi-Aventis closed at $39.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Upgrades

Related Entities

Earnings

Add Your Comment